Results 31 to 40 of about 19,188,680 (306)

Dolutegravir for second-line treatment: Programmatic implications of new evidence

Southern African Journal of HIV Medicine, 2022
No abstract available.
Ying Zhao, Gary Maartens, Graeme Meintjes   +2 more
doaj   +1 more source

Phage Therapy Potentiates Second-Line Antibiotic Treatment against Pneumonic Plague

Viruses, 2022
Plague pandemics and outbreaks have killed millions of people during the history of humankind. The disease, caused by the bacteria Yersinia pestis, is currently treated effectively with antibiotics.
Yaron Vagima, David Gur, Moshe Aftalion, Sarit Moses, Yinon Levy, Arik Makovitzki, Tzvi Holtzman, Ziv Oren, Yaniv Segula, Ella Fatelevich, Avital Tidhar, Ayelet Zauberman, Shahar Rotem, Emanuelle Mamroud, Ida Steinberger-Levy   +14 more
doaj   +1 more source

Consequences of targeted treatments for second-line therapy

Annals of Oncology, 2010
The paradigm for first-line treatment of relapsed or metastatic non-small cell lung cancer (NSCLC) is changing. Large phase III trials demonstrated that, in 2010, we cannot select a therapy without an accurate definition of tumor histology and epidermal growth factor receptor (EGFR) status.
E, De Maio, C, Tibaldi, A, D'Incecco, S, Bursi, C, Barbara, S, Cupini, R, Di Marsico, M, D'Arcangelo, L, Landi, G, Minuti, F, Cappuzzo   +10 more
openaire   +2 more sources

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. [PDF]

, 2012
BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy.
Alec Miners, Valentina Cambiano (146513), von Wyl Viktor, Phillips, Andrew N, Andrew N Phillips, Jens Lundgren, Valentina Cambiano, Silvia Bertagnolio, Pillay Deenan, Pillay, Deenan, Deenan Pillay (7888), Bertagnolio, Silvia, Miners Alec, Michael R. Jordan (146520), Cambiano, Valentina, von Wyl, Viktor, Viktor von Wyl, Phillips Andrew N., Jordan, Michael R, Cambiano Valentina, Miners, Alec, Bertagnolio Silvia, Lundgren Jens, Andrew N. Phillips (146556), Lundgren, Jens, Alec Miners (146534), Viktor von Wyl (146506), Silvia Bertagnolio (57174), Michael R Jordan, Deenan Pillay, Jens Lundgren (146550), Jordan Michael R.   +31 more
core   +2 more sources

Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study

BMC Infectious Diseases, 2019
Background Currently, there is limited evidence on the effectiveness of second-line antiretroviral therapy (ART) in sub-Saharan Africa. To address this challenge, outcomes of second-line protease inhibitor (PI) based ART in Rwanda were assessed.
Sabin Nsanzimana, Muhammed Semakula, Vedaste Ndahindwa, Eric Remera, Dieudonne Sebuhoro, Jean Paul Uwizihiwe, Nathan Ford, Marcel Tanner, Steve Kanters, Edward J. Mills, Heiner C. Bucher   +10 more
doaj   +1 more source

Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis

Cancer Medicine, 2022
Background Although second‐line treatment for pancreatic cancer has been proven to have survival benefit, it is not clear which is the most preferred regimen. This study compared the efficacy and safety of modified FOLFIRINOX (mFOLFIRINOX) and sequential
Shun Tezuka, Makoto Ueno, Ritsuko Oishi, Shuhei Nagashima, Yusuke Sano, Kuniyuki Kawano, Satoshi Tanaka, Taito Fukushima, Hiroyuki Asama, Naoki Konno, Satoshi Kobayashi, Manabu Morimoto, Shin Maeda   +12 more
doaj   +1 more source

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia

, 2020
Rituximab-containing chemotherapy remains a viable frontline treatment option for patients with chronic lymphocytic leukemia (CLL) in the era of novel agents.
Kater, Arnon P., van der Straten, Lina, Levin, Mark-David, van den Broek, Esther C., Dinmohamed, Avinash G., Doorduijn, Jeanette K., Posthuma, Eduardus F. M.   +6 more
core   +1 more source

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration [PDF]

, 2011
Article approval pendingWith expanding pediatric antiretroviral therapy (ART) access, children will begin to experience treatment failure and require second-line therapy. We evaluated the probability and determinants of virologic failure and switching in
Technau K., Olivia Keiser, Rabie, Helena, Giddy, Janet, Egger, Matthias, Davies M.-A., Eley, Brian, Van Cutsem, Gilles, Harry Moultrie, Janet Giddy, Karl Technau, Moultrie H., Helena Rabie, Eley B., Giddy J., Egger M., Robin Wood, Technau, Karl, Rabie H., Van Cutsem G., Gilles Van Cutsem, Matthias Egger, Keiser, Olivia, Brian Eley, Moultrie, Harry, Boulle, Andrew, Mary-Ann Davies, Davies, Mary-Ann, Andrew Boulle, Boulle A., Keiser O., Wood R., Wood, Robin   +32 more
core   +3 more sources

Rate of patients receiving second-line treatment for metastatic colorectal cancer in a real-world setting

, 2021
Background: Colorectal cancer is the third most common cancer diagnosed in Australia. Although a large portion (46.4%) present at an early stage, up to 45% relapse and many others present with de novo metastatic disease.1, 2 Although the treatment ...
Ups, Katherine, Ryan, Elizabeth G, Francesconi, Alessandra   +2 more
core   +1 more source